Tools   Select Another Resource Report Type

https://meded.ucsd.edu/index.cfm/asa/dcp/goddp/

The UCSD School of Medicine are dedicated to producing future leaders in all areas of medicine. As such, the School promotes the pursuit of dual degrees, either in the Medical School's own graduate degree programs or programs offered in other disciplines in the institution. In addition to the study of medicine, the School of Medicine actively encourages its student body to explore broadly in various scholarly areas related to the biomedical sciences. The goal of this additional training is to produce graduates who will bring fresh, innovative ideas to the research laboratory, the public health sector, the humanities and the social sciences, and the business environment. Students may elect to obtain advanced degrees in the following areas: * Biomedical Sciences * Masters in Bioengineering * Masters in Public Health * Masters in Leadership of Health Care Organizations * Masters of Advanced Studies in Clinical Research * Ph.D. Program in the Humanities and Social Sciences * Independent Ph.D. programs Opportunities for enrollment in research or degree programs outside of UCSD are also available, and students are encouraged to investigate these, if interested. Sponsors: This program is supported by the University of California at San Diego.

Proper citation: University of California at San Diego, School of Medicine: Graduate Opportunities & Dual Degree Programs (RRID:SCR_001942) Copy   

•   Source: SciCrunch Registry

http://www.bioon.com/bioline/neurosci/course/index.htm

An illustrated guide to the essential basics of clinical neuroscience created in conjunction with the first-year course for medical students.
Topics covered:
* Coronal and horizontal sections
* Basic visual pathway
* Basic somatosensory pathway
* Basic motor pathway
* Eye and retina
* Central visual pathways
* Auditory and vestibular systems
* Somatosensory pathways from the body
* Somatosensory pathways from the face
* Spinal motor structures
* Brainstem nuclei of cranial nerves
* Basal ganglia and cerebellum
* Hypothalamus and autonomic nervous system
* Medial temporal lobe and memory
* Sleep and language
* Where is...?

Proper citation: Washington University School of Medicine Neuroscience Tutorial (RRID:SCR_002271) Copy   

•   Source: SciCrunch Registry

http://www.humgen.rwth-aachen.de/

Catalog of all changes detected in PKHD1 (Polycystic Kidney and Hepatic Disease 1) in a locus specific database. Investigators are invited to submit their novel data to this database. These data should be meaningful for clinical practice as well as of relevance for the reader interested in molecular aspects of polycystic kidney disease (PKD). There are also some links and information for ARPKD patients and their parents. Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61%. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges.

Proper citation: Autosomal Recessive Polycystic Kidney Disease Mutation Database (RRID:SCR_002290) Copy   

•   Source: SciCrunch Registry

http://selectscience.net

SelectScience.net is a leading online resource for applied chemists, clinical chemists and life scientists. It provides up-to-date product and industry news, an extensive product directory and end-user product reviews, as well as the ability for visitors to review the products they use. Scientists can also use the site to search for jobs, application notes and scientific conferences. Sponsors: The company is run by independent scientists and funded from Government and Corporate sponsorship.

Proper citation: SelectScience (RRID:SCR_002733) Copy   

•   Source: SciCrunch Registry

http://www.cpdd.vcu.edu/

The College on Problems of Drug Dependence (CPDD) is an interdisciplinary research society whose members address problems of drug dependence in the broadest range of scientific disciplines, including chemistry, basic biology, pharmacology, behavioral science, clinical research, sociology, psychology, anthropology, and history. CPDD serves as an interface among governmental, industrial and academic communities maintaining liaisons with regulatory and research agencies as well as educational, treatment, and prevention facilities in the drug abuse field. It also functions as a collaborating center of the World Health Organization. The Annual Scientific Meeting: Since 1938, a major focus of the CPDD's activities has been its sponsorship of an annual scientific meeting. This conference serves as a forum bringing together basic scientists and clinical investigators from industry, academia, and government. Representatives of regulatory agencies, as well as scientists and professionals in a number of diverse disciplines interested in the biochemical, behavioral, and public health aspects of drug dependence participate. Special Conferences: Periodically, the College sponsors conferences focused on timely topics of interest to researchers, government, industry, and the public. In recent years, CPDD has organized meetings on Abuse Liability Assessment of CNS Drugs; Drug Formulation and Abuse Liability; Pre-Clinical Abuse Liability Testing; Women and Smoking: Understanding Socioeconomic Influences; and Risk Management and Post-Marketing Surveillance for CNS-Acting Drugs. Consultation Activities: The CPDD provides consulting expertise in the area of epidemiology, treatment, prevention, and all the basic and clinical sciences related to drug dependence, drug abuse, and their behavioral and medical consequences. Sponsorship of Drug and Alcohol Dependence: The CPDD sponsors the journal Drug and Alcohol Dependence, published by Elsevier. A principal goal of the journal is to provide a source of quality, timely reports of scientific advances in substance abuse research. The journal is international in scope and interdisciplinary in coverage. The CPDD invites contributors. Donations Tax-deductible donations can be made to CPDD to support the Annual Scientific Meeting, testing facilities, drug assessment activities and Awards for Excellence.

Proper citation: College on Problems of Drug Dependence (RRID:SCR_002618) Copy   

•   Source: SciCrunch Registry

http://www.wanprc.org/

Center that aims to provide an environment to support biomedical research directed towards human health issues and nonhuman primate health and biology. To meet this mission, the WaNPRC supports biomedical research activities, professional research staff, specifically bred and maintained nonhuman primate colonies, and dedicated facilities and equipment required for nonhuman primate research protocols.

Proper citation: Washington National Primate Research Center (RRID:SCR_002761) Copy   

•   Source: SciCrunch Registry

http://www.mrc-cbu.cam.ac.uk/Imaging

Portal where neuroimaging studies are carried out using a Siemens 3T Tim Trio Magnetic Resonance Imaging (or MRI) scanner that is wholly dedicated to studies in Cognitive Neuroscience. From emotions and memories to language and learning, functional neuroimaging is being applied in many different areas of Cognitive Neuroscience. In many cases, this research relies upon support from healthy volunteers although neuroimaging studies are also being conducted in various clinical populations, including depression, anxiety, Parkinson's disease and Alzheimer's disease.

Proper citation: CBU Imaging Wiki (RRID:SCR_003014) Copy   

•   Source: SciCrunch Registry

http://www.xnat.org

Software platform designed to facilitate common management and productivity tasks for neuroimaging and associated data.

Proper citation: XNAT - The Extensible Neuroimaging Archive Toolkit (RRID:SCR_003048) Copy   

•   Source: SciCrunch Registry

http://www.biomarkersconsortium.org/

Consortium serving to develop and qualify promising biomarkers in order to help accelerate the delivery of successful new technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease. Current core disease areas of focus include Cancer, Inflammation and Immunity, Metabolic Disorders, and Neuroscience. One of the most difficult tasks facing biomarker assessment and evaluation is harmonizing the approaches of various stakeholders--government, industry, non-profits and foundations, providers, and academic institutions. Consortium founding members and other partners recognize the critical need for a coordinated cross-sector partnership effort. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers. Biomarkers Consortium Goals: * Facilitate the development and qualification of biomarkers using new and existing technologies; * Help qualify biomarkers for specific applications in diagnosing disease, predicting therapeutic response or improving clinical practice; * Generate information useful to inform regulatory decision making; * Make consortium project results broadly available to the entire scientific community.

Proper citation: Biomarkers Consortium (RRID:SCR_003121) Copy   

•   Source: SciCrunch Registry

http://talkbank.org/

Databases of transcript and media data collected from conversations with adults and older children to foster fundamental research in the study of human and animal communication. Conversations with children are available from CHILDES. All of the data is transcribed in CHAT and CA/CHAT formats. Databases of the following types are included in the collection: Aphasia patient speech, Child speech, Study of Phonological Development, Conversation Analysis, and Bilingualism and Second Language Acquisition. TalkBank will use these databases to advance the development of standards and tools for creating, sharing, searching, and commenting upon primary materials via networked computers.

Proper citation: TalkBank (RRID:SCR_003242) Copy   

•   Source: SciCrunch Registry

http://empress.har.mrc.ac.uk

Database of validated Standard Operating Procedures (SOPs) for screens to determine the phenotype of a mouse, developed by the EUMORPHIA consortium. The SOP's cover all of the main body systems including: clinical chemistry, hormonal and metabolic systems, cardiovascular, allergy and infection, renal function, sensory function, neurological and behavioral function, cancer, bone and cartilage, and respiratory function. In addition, there are generic SOPs in histology, necropsy, pathology and gene expression. EMPReSS is a platform of individual tests. These can be performed as individual tests or grouped together in sequences, recommended in the EMPReSS database, to give more information on particular phenotype. Quick List of Current Pipelines: * EUMODIC Pipeline 1 * EUMODIC Pipeline 2 * GMC Pipeline * MGP Pipeline * Additional Tests * EUMODIC Pipeline 3

Proper citation: European Mouse Phenotyping Resource of Standardised Screens (RRID:SCR_003087) Copy   

•   Source: SciCrunch Registry

http://www.globalhealthlibrary.net/php/index.php

The Global Health Library assembles health data, readable in many languages. The GHL aims to: * point to reliable information collections and systems, in which different users and user groups (ministries of health, policy makers, health workers, information providers, patients and their families, general public) can focus on the knowledge that best meets their health information needs; * act as a facilitator enabling access to information contents produced by numerous key providers - be they commercial companies, government institutions, civil society, not-for-profit organizations, and regional or international bodies; and * strive for universality, with focus on developing countries, and will act as a resource locator for print materials essential to areas that do not have access to electronic content.

Proper citation: World Health Organization: The Global Health Library (RRID:SCR_000391) Copy   

•   Source: SciCrunch Registry

http://www.drugabuseresearchtraining.org/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on November 07, 2012. Decemeber 15, 2011 - Thank you for your interest in DrugAbuseResearchTraining.org. The site, courses, and resources are no longer available. Please send an email to inquiry (at) md-inc.com if you would like to be notified if the site or courses become available again. Introduction to Clinical Drug and Substance Abuse Research Methods is an online training program intended to introduce clinicians and substance abuse professionals to basic clinical research methods. The program is divided into four modules. Each module covers an entire topic and includes self-assessment questions, references, and online resources: * The Neurobiology of Drug Addiction * Biostatistics for Drug and Substance Abuse Research * Evaluating Drug and Substance Abuse Programs * Designing and Managing Drug and Substance Abuse Clinical Trials The learning objectives of this program are to help you: * Evaluate the benefits of alternative investigative approaches for answering important questions in drug abuse evaluation and treatment. * Define the proper levels of measurement and appropriate statistical methods for a clinical study. * Address common problems in data collection and analysis. * Anticipate key human subjects and ethical issues that arise in drug abuse studies. * Interpret findings from the drug abuse research literature and prepare a clinical research proposal. * Prepare research findings for internal distribution or publication in the peer reviewed literature. * Recognize drug addiction as a cyclical, chronic disease. * Understand and describe the brain circuits that are affected by addicting drugs, and explain to others the effects of major classes of addicting drugs on brain neurotransmitters. * Utilize new pharmacologic treatments to manage persons with drug addiction. Physicians can earn AMA PRA Category 1 Credit and purchase a high resolution printable electronic CME certificate(view sample); non-physicians can purchase high resolution printable electronic certificate of course participation that references AMA PRA Category 1 credit (view sample). This program does not offer printed certificates.

Proper citation: Online Education for the International Research Community: AboutIntroduction to Clinical Drug and Substance Abuse Research Methods (RRID:SCR_000802) Copy   

•   Source: SciCrunch Registry

http://www.genet.sickkids.on.ca/cftr/

Collection of mutations in CFTR gene for international cystic fibrosis genetics research community. Provides up to date information about individual mutations in CFTR gene. All known CFTR mutations and sequence variants have been converted to standard nomenclature recommended by Human Genome Variation Society. On line process for submission of new mutations has been added.While they continue to ensure quality of data, they urge international community to give them feedback and suggestions. Clinical information in this database relates only to details of discovery of specific mutations. As part of 2010 upgrade, CFTR1 joined new project called CFTR2 - Clinical and Functional TRanslation of CFTR. Links to CFTR2 for many mutations in CFTR1 will provide up-to-date summaries of genotype-phenotype information from patient registries around the world.

Proper citation: Cystic Fibrosis Mutation Database (RRID:SCR_000685) Copy   

•   Source: SciCrunch Registry

http://www.ninds.nih.gov/funding/nindsnotes/200707/NIH%20Rapid%20Access%20to%20Interventional%20Development.htm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 14, 2025.NIH-RAID makes available at no cost to researchers and organizations certain critical resources needed for the development of new therapeutic agents. This program, part of the Translational Research component of Reengineering the Clinical Research Enterprise, uses resources of NCI's Developmental Therapeutics Program and the National Heart Lung and Blood Institutes (NHLBI) Gene Therapy Resource Program. The services provided will depend upon the stage of the project and the strength of the preliminary data. Services available include: production, bulk supply, GMP manufacturing, formulation, development of an assay suitable for pharmacokinetic testing, and animal toxicology. Assistance also will be provided in the regulatory process, through access to independent product development planning expertise. Proposals in support of animal efficacy studies or synthesis and formulation of recombinant proteins or monoclonal antibodies will not be accepted. NIH-RAID is not a grant program. Successful projects will gain access to the governments contract resources, as well as the assistance of the NIH in establishing and implementing a product development plan. Funds to support individual projects will come both from the Roadmap and from individual Institutes, with Institutes assuming the bulk of support in the specific disease areas germane to their mission. This co-sponsorship is critical because of the resource and expertise needs and because NIH-RAID cannot support the full developmental pipeline; an Institute partnership may therefore be important for subsequent translational efforts. To obtain access to NIH-RAID resources, applications must be submitted electronically through Grants.gov using SF424. Applications are initially screened to determine whether the resources requested are appropriate for this program. Then they are reviewed by the NIH Center for Scientific Research. The results of that evaluation along with supplemental information from the lead investigator will guide final Institute and Roadmap resource allocation. The services provided will depend upon the stage of the project and the strength of the preliminary data. When a lead therapeutic agent has been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Scale-up production, Development of analytical methods, Development of suitable formulations, Isolation and purification of natural products, Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Manufacture of clinical trial supplies, Product development planning and advice in IND preparation For recombinant proteins and monoclonal antibodies: Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Product development planning and advice in IND preparation When a lead therapeutic agent has not yet been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Development of analytical methods, Isolation and purification of natural products, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology For recombinant proteins and monoclonal antibodies, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology In some cases the NIH-RAID program will support only one or two key steps for preclinical development, while in other cases it may be possible to provide assistance with most of the development tasks needed to file an Investigational New Drug (IND) application to the Food and Drug Administration (FDA). When the NIH-RAID program does not provide all of the remaining services required for IND submission, it is expected that other resources will be in place to complete development steps not supported by NIH-RAID. Funding Resource,.

Proper citation: NIH - Rapid Access to Interventional Development (RRID:SCR_000713) Copy   

•   Source: SciCrunch Registry

http://hospitals.jefferson.edu/diseases-and-conditions/alzheimers-disease/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 6,2023. If you or someone you love has been diagnosed with dementia caused by Alzheimer's disease, you'll be in good hands at Jefferson. Our neurologists and psychiatrists are dedicated to: Compassionate care for individuals with Alzheimer's disease; Supporting families; Advancing care through research into the epidemiology and treatment of neurodegenerative diseases. We interact with patients very early in the disease progression, when impairment is typically mild; deliver state-of-the-art care; provide information; build care-giving skills; and help caregivers connect with community support and plan for the future.

Proper citation: Jefferson Hospital for Neuroscience Alzheimers Disease and Dementia Center (RRID:SCR_000579) Copy   

•   Source: SciCrunch Registry

http://www2.gsu.edu/~wwwvir/index.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 18,2025. The National B Virus Resource Center is located in the Viral Immunology Center of Georgia State Universitys Department of Biology. Their laboratory is studying viruses that directly affect the central nervous system of infected hosts. Current projects in the laboratory are focused on the molecular biology of human and nonhuman primate alphaherpesviruses and the diseases they cause, immune response characterization, antiviral strategies, including drug discovery and high-throughput drug screening within unique, high containment laboratory suites. They are also actively engaged in the study of unique reoviruses that have the capacity to infect the central nervous systems of non human primates, langur viruses, and a newly isolated mangaby herpesvirus. Alphaherpesviruses target the central nervous system of susceptible hosts, and subsequently establish latent infections generally without severely damaging the host. There may be an initial acute phase when the virus successfully replicates in peripheral tissue of the host. This replication, when it occurs, induces a series of specific immune functions that can serve as markers of infection. We use these markers to design, develop and implement diagnostic assays that will be useful during the management of clinical disease. Each herpesvirus coexists peacefully with the natural host in which it has co-evolved, but when the viruses for any reason find themselves no longer in the natural host, the usual host:parasite relationship may change dramatically. In some closely related hosts the virus can replicate and, in some cases, pathogenesis of the infection is radically more severe than that which occurs in the natural host. For example, this can be seen when New World monkeys are infected with humans herpesviruses, e.g., HSV-1 or HSV-2, or when humans are infected with B virus from a macaque, a member of the Old World monkey family. Their studies focus on the mechanisms by which virus kills the host and how that process can be circumvented with early identification, appropriate antiviral drugs, and in the future, effective vaccines. We continually screen the efficacy of existing as well as novel antiviral agents to inhibit the growth of viruses that can potentially cross into the human population, either through occupational exposure or through more subtle contact. Their laboratory provides a global resource funded by National Institutes of Healths National Center for Research Resources to assist in the identification of zoonotic disease transmissions and develop enhanced strategies to detect virus in macaques. They particularly focus on the transmission of B virus from Asian monkeys to humans who come in contact with them. Members of the genus Macaca include rhesus monkeys, cynomolgus macaques, snow macaques, as well as all other macaques. If the macaque is in the midst of the acute or recurrent infection with B, virus can be transmitted to people who handle these monkeys through cuts, scratches, splashes, bites, or even contaminated equipment or surfaces, i.e., fomites. To counter the effects of this virus, the NIH and Centers for Disease Control and Prevention have instituted a critical set of guidelines for institutions to follow in the event of exposures. Their laboratory provides immediate support to these cases to assist in the rapid diagnosis of B virus infections and to determine the efficacy of selected treatment. Lifetime patient monitoring is provided to identify possible reactivation disease and to better track this unique herpesvirus as it has begun its existence in the human populations. Sponsors: The viral immunology center is funded by National Institutes of Healths National Center for Research Resources.

Proper citation: Viral Immunology Center (RRID:SCR_001089) Copy   

•   Source: SciCrunch Registry

https://medschool.vanderbilt.edu/pharmacology/

At the Department of Pharmacology at Vanderbilt University Medical Center we engage in scientific discovery to elucidate biological mechanisms and develop novel therapeutics. We provide training focused on critical thinking to promote innovation, scholarship and integrity. To this end, we foster creativity, collegiality, and leadership. The Department is one of the most distinguished Pharmacology departments in the country and have placed in the top two NIH ranking positions for sixteen of the last twenty years. Research interests in the Department include five major areas: signal transduction, neuroscience, bioactive lipid metabolism, genetic basis of cardiovascular dysfunction, and drug metabolism. Molecules under investigation include G-protein coupled receptors (rhodopsin, adrenergic, serotonin and receptors), heterotrimeric G-proteins, ion channels, transporters and regulatory proteins such as arrestins, protein kinases and protein phosphatases. A strength in our research and training environment is that Vanderbilt University has a world-acclaimed Division of Clinical Pharmacology, which links the Department of Medicine with the Department of Pharmacology. Faculty members in the Division of Clinical Pharmacology focus on human disease and clinical enigmas as the origin of their questions for research. Basic scientists who pursue their inquiries in this environment are continually informed by their colleagues of the pathophysiological and potential therapeutic relevance that can be achieved by appropriate focus of their efforts. We have created one of the first programs in the country to answer the call from the National Institutes of Health (NIH) for more scientists trained in the area of drug discovery and development. A unique feature of the department is our outstanding Ph.D. training program. Almost 60 scientists in training are addressing important issues in fields such neuroscience, cardiovascular development, receptor signaling, and drug metabolism. Scientists in these areas are linked by a common interest in, and understanding of, the basic principles of drug action and design. This perspective makes our trainees ideally suited for a wide range of careers and our program is committed to developing leaders in academia, industry, and regulatory affairs. Postdoctoral and other positions are available.

Proper citation: Vanderbilt University Medical Center Pharmacology (RRID:SCR_001450) Copy   

•   Source: SciCrunch Registry

http://www.pd-doc.org/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on December 02, 2011. Notice: This domain name expired on 10/29/11 and is pending renewal or deletion PD-DOC is a portal and a database resource, hosting a database and linking to other databases and data sets of clinical and translational data. PD-DOC functions to organize and facilitate clinical and translational research in Parkinson's disease. The PD-DOC Database contains standardized data collected by user institutions on large numbers of patients with Parkinsons disease and other parkinsonian disorders. In some cases, data is obtained at a single point in time, while in others data is collected repeatedly over time. The PD-DOC Database is composed of the Core Data Set (CDS) which consists of those variables required to be gathered for each subject whose data is entered into the PD-DOC database. In 2005, working groups of Udall Center and invited experts deliberated to establish the components of each CDS section (e.g. General Clinical, Cognitive/Behavioral, Postmortem Brain Neuropathological Findings). The PD-DOC CDS was established and designed to optimize data analyses and data mining for large numbers of subjects participating in a variety of research studies. In most cases corresponding DNA samples are available form the NINDS Human Genetic Repository (at Coriell). Much of the website is publicly available for viewing. To request access to sections of the website dealing with downloading or requesting data, requesting a consultation, or submitting data or other information you will need to register. Before registering, you should read the PD-DOC Policies. Note that PD-DOC data can be used for research purposes only. Once your registration is successfully completed you will be automatically logged into the website.

Proper citation: PD-DOC (RRID:SCR_001596) Copy   

•   Source: SciCrunch Registry

https://edic.bsc.gwu.edu

Publications from a multi-center, longitudinal, observational study examining the risk factors associated with the long-term complications of type 1 diabetes. The study began in 1994 and follows the 1441 participants previously enrolled in the Diabetes Control and Complications Trial (DCCT), http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx. The primary aim of EDIC is to examine the long-term effects of conventional vs. intensive diabetes treatment received during the DCCT on the subsequent development and progression of microvascular, neuropathic and cardiovascular complications. This involves studying the influence of genetic factors and other factors such as HbA1c, blood pressure, lipid levels, and treatment modalities on the development and progression of these complications. Annual or biennial measurements (using DCCT methods, standardized protocols and central laboratories) of vascular events, albumin excretion, GFR, ECG, ankle-brachial BP index, serum lipids and HbA1c allows the following analyses: 1) continuation of intention-to-treat analyses to determine long-term effects of prior separation of glycemic levels; 2) risk factors for macrovascular outcomes; 3) correlation of progression of micro- and macrovascular outcomes. The current updated version of the EDIC Protocol is available for download. EDIC is made up of 28 clinical centers, one data coordinating center and one clinical coordinating center.

Proper citation: Epidemiology of Diabetes Interventions and Complications (RRID:SCR_001468) Copy   

•   Source: SciCrunch Registry